Sugi Predict

Sugi Predict / Targets / KLRK1

KLRK1

NKG2-D type II integral membrane protein (Kil · P26718 · KLRK1 on Sugi Atlas →

2,186 patent compounds predicted against KLRK1, 546 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3919085 SCHEMBL3919085 0.64 16/20
SCHEMBL8235992 SCHEMBL8235992 0.59 16/20
SCHEMBL8235594 SCHEMBL8235594 0.46 13/20
SCHEMBL20743022 SCHEMBL20743022 0.49 11/20
SCHEMBL8227997 SCHEMBL8227997 0.47 11/20
SCHEMBL4488563 SCHEMBL4488563 0.45 11/20
SCHEMBL7745771 SCHEMBL7745771 0.57 9/20
SCHEMBL15388874 SCHEMBL15388874 0.51 9/20
SCHEMBL8232539 SCHEMBL8232539 0.45 9/20
SCHEMBL22048232 SCHEMBL22048232 0.38 9/20
SCHEMBL1307758 SCHEMBL1307758 0.54 8/20
SCHEMBL1309664 SCHEMBL1309664 0.53 8/20
SCHEMBL18705673 SCHEMBL18705673 0.38 8/20
SCHEMBL1308440 SCHEMBL1308440 0.53 7/20
SCHEMBL5106559 SCHEMBL5106559 0.40 7/20
SCHEMBL6850836 SCHEMBL6850836 0.55 6/20
SCHEMBL6706746 SCHEMBL6706746 0.54 6/20
SCHEMBL13485786 SCHEMBL13485786 0.53 6/20
SCHEMBL20665433 SCHEMBL20665433 0.52 6/20
SCHEMBL1350744 SCHEMBL1350744 0.50 6/20

Clinical trials — most relevant to KLRK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma PHASE3COMPLETED
Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT PHASE1/PHASE2COMPLETED
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant PHASE2COMPLETED
The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 PHASE2NOT_YET_RECRUITING
Haploidentical NK-cell Infusion in Acute Myeloid Leukemia PHASE1/PHASE2COMPLETED
A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies PHASE1/PHASE2UNKNOWN
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies PHASE1/PHASE2WITHDRAWN
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 PHASE1/PHASE2COMPLETED
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) PHASE2WITHDRAWN
A Phase 1/2 Study to Evaluate MEDI4736 PHASE1/PHASE2COMPLETED
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma PHASE2COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL. PHASE2WITHDRAWN
Cetuximab and Lenalidomide in Head and Neck PHASE2COMPLETED
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma PHASE1ACTIVE_NOT_RECRUITING
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors PHASE1UNKNOWN
Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell (SMT-NK) Cell Therapy in Advanced Biliary Tract Cancer PHASE1COMPLETED
Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia PHASE1SUSPENDED
An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma EARLY_PHASE1UNKNOWN
Assessment of Natural Killer Cells in Unexplained Recurrent Pregnancy Loss nanUNKNOWN
TIGIT in Patients With Chronic Myeloid Leukemia nanUNKNOWN
Genetic Analysis of Psoriasis and Psoriatic Arthritis nanCOMPLETED
HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS) nanCOMPLETED
Innate Immunity, MIcrobiota and Inovative Treatments in Endometriosis nanNOT_YET_RECRUITING
KIR Genes and Non-Celiac Wheat Sensitivity nanCOMPLETED
Single-Cell Profiling of Liver-infiltrating Immune Cells of Patients with NASH- and Virus-related HCC: Implications for Immunotherapy nanCOMPLETED
Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19. nanCOMPLETED
Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence nanUNKNOWN
Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer nanCOMPLETED
Relationship Between Breast Cancer Subtypes and Immune Checkpoints nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KLRK1 binder may also engage these)

ProteinNameSimilarity
Q9MZ37 — 1.000 Q9MZ37 →
P61252 — 1.000 P61252 →
Q9MZJ7 — 1.000 Q9MZJ7 →
Q8MJH1 — 1.000 Q8MJH1 →
O54709 — 0.994 O54709 →
O70215 — 0.993 O70215 →
Q9GLF5 — 0.993 Q9GLF5 →
Q80XD9 — 0.988 Q80XD9 →
A4KWA8 — 0.988 A4KWA8 →
A4KWA5 — 0.987 A4KWA5 →
Q91V08 — 0.987 Q91V08 →
P26717 — 0.985 P26717 →
Q8C1T8 — 0.985 Q8C1T8 →
Q07444 — 0.985 Q07444 →
P27811 — 0.984 P27811 →
Q9WVF9 — 0.984 Q9WVF9 →
Q60652 — 0.984 Q60652 →
Q8MI05 — 0.984 Q8MI05 →
Q8VI21 — 0.984 Q8VI21 →
Q925N7 — 0.984 Q925N7 →
Q60654 — 0.983 Q60654 →
Q80ZC8 — 0.983 Q80ZC8 →
Q95MI4 — 0.983 Q95MI4 →
Q6QLQ4 — 0.983 Q6QLQ4 →
Q8CJC7 — 0.982 Q8CJC7 →
CD69 Early activation antigen CD69 0.982 landscape →
Q9D676 — 0.982 Q9D676 →
Q0H8B9 — 0.981 Q0H8B9 →
P20937 — 0.980 P20937 →
Q60651 — 0.980 Q60651 →